Abstract:
BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase in transaminases whilst taking agomelatine. METHOD:A retrospective pooled analysis of changes in transaminase levels in 9234 patients treated with agomelatine (25 or 50 mg/day; n = 7605) or placebo (n = 1629) from 49 phase II and III studies was undertaken. A significant increase in transaminase levels was defined as an increase to >3 times the upper limit of normal (ULN) (>3 × ULN). Final causality was determined in a case-by-case review by five academic experts. RESULTS:Serum transaminases increased to >3 × ULN in 1.3 and 2.5 % of patients treated with 25 and 50 mg of agomelatine, respectively, compared with 0.5 % for placebo. The onset of increased transaminases occurred before 12 weeks in 64 % of patients. The median time to recovery (to ≤2 × ULN) was 14 days following treatment withdrawal. Liver function tests recovered in 36.1 % of patients despite continuation of agomelatine, suggesting the presence of a liver adaptive mechanism. No cases of acute liver failure or fatal outcome occurred. Patients with elevated transaminases at baseline, secondary to obesity/fatty liver disease, had an equally increased risk of developing further elevations of transaminases with agomelatine and placebo. CONCLUSION:Incidence of abnormal transaminases was low and dose dependent. No specific population was identified regarding potential risk factors. Withdrawal of agomelatine led to rapid recovery, and some patients exhibited an adaptive phenomenon. Overall, in clinical trials, the liver profile of agomelatine seems safe when serum transaminases are monitored.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore Kdoi
10.1007/s40263-016-0351-6subject
Has Abstractpub_date
2016-09-01 00:00:00pages
877-88issue
9eissn
1172-7047issn
1179-1934pii
10.1007/s40263-016-0351-6journal_volume
30pub_type
杂志文章,meta分析相关文献
CNS DRUGS文献大全abstract::In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418120-00005
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0102-x
更新日期:2013-11-01 00:00:00
abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11590450-000000000-00000
更新日期:2011-06-01 00:00:00
abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199809040-00003
更新日期:1998-04-01 00:00:00
abstract::Neuropathic pain is a persistent pain condition that develops secondary to nerve injury. The two most common types of peripheral neuropathic pain are post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Amitriptyline, nortriptyline, desipramine and imipramine are TCAs that have been shown to be effecti...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200822050-00005
更新日期:2008-01-01 00:00:00
abstract:OBJECTIVE:To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks. METHODS:This was a two-phase, multicentre, randomised, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 2...
journal_title:CNS drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2165/00023210-200620120-00005
更新日期:2006-01-01 00:00:00
abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11633910-000000000-00000
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...
journal_title:CNS drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s40263-018-0586-5
更新日期:2019-01-01 00:00:00
abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0548-y
更新日期:2018-08-01 00:00:00
abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-017-0427-y
更新日期:2017-06-01 00:00:00
abstract::How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0288-1
更新日期:2015-11-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11208340-000000000-00000
更新日期:2011-10-01 00:00:00
abstract::Topiramate is an antiepileptic drug that has a broad spectrum of antiseizure effects, which appear to be the result of several neurostabilising pharmacological mechanisms. These include blockade of ion channels, potentiation of GABA neuroinhibition and glutamate receptor antagonism at non-NMDA receptors, as well as mi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317130-00007
更新日期:2003-01-01 00:00:00
abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-015-0307-2
更新日期:2016-02-01 00:00:00
abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11595060-000000000-00000
更新日期:2011-11-01 00:00:00
abstract:OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200216040-00006
更新日期:2002-01-01 00:00:00
abstract::Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11207350-000000000-00000
更新日期:2011-08-01 00:00:00
abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00756-y
更新日期:2020-09-01 00:00:00
abstract::Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0110-x
更新日期:2013-10-01 00:00:00
abstract::Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115020-00004
更新日期:2001-01-01 00:00:00
abstract::Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00754-0
更新日期:2020-10-01 00:00:00
abstract::Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0134-2
更新日期:2014-02-01 00:00:00
abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00641-3
更新日期:2019-08-01 00:00:00
abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0301-8
更新日期:2015-12-01 00:00:00
abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216100-00002
更新日期:2002-01-01 00:00:00
abstract::Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and lon...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721070-00004
更新日期:2007-01-01 00:00:00
abstract::Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there h...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0089-3
更新日期:2013-09-01 00:00:00
abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200317120-00005
更新日期:2003-01-01 00:00:00
abstract::The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00620-8
更新日期:2019-04-01 00:00:00
abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923060-00006
更新日期:2009-01-01 00:00:00